PCSK9 and familial hypercholesterolemia: The third study, sponsored by Verve Therapeutics, was the first to evaluate a base editing platform using an ABE to disrupt the expression of the PCSK9 gene, to treat heterozygous familial hypercholesterolemia (ClinicalTrials, 2024d).